Article Text

Download PDFPDF
Duovent – is logic enough?

Abstract

Duovent (WB Pharmaceuticals) is a fixed-dose combination aerosol containing fenoterol (100 μg per puff) - a β2-adrenoceptor stimulant, and ipratropium (40 μg per puff) - an atropine-like agent. It is marketed for the treatment of bronchoconstriction in patients with asthma, chronic bronchitis or emphysema. The manufacturer claims that it is a ‘logical combination’ offering ‘first line treatment’, but the British National Formulary1 states that compound bronchodilators (including Duovent) ‘have no place in the management of patients with airways obstruction’.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.